Back to search results

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumors · Breast Cancer Recurrent · Ovarian Cancer · High-grade Serous Ovarian Carcinoma · Triple Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Florida Cancer Specialists, Sarasota, Florida, United States

    Contact: Study coordinator (Latisha Hall) · 941-377-9993
    Contact: Principal Investigator (Judy Wang, MD)

  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Davonna Felder) · felderd@karmanos.org · 313-576-9014
    Contact: Principal Investigator (Wasif Saif, MD)

  • SCRI Oncology Partners, Nashville, Tennessee, United States

    Contact: Study coordinator (Latisha Hall) · 615-329-7640
    Contact: Principal Investigator (Deepak Bhamidipati, MD)

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Timothy Yap, MD, PhD) · tyap@mdanderson.org · 713-563-1784
    Contact: Principal Investigator (Timothy Yap, MD, PhD)

  • NEXT Oncology, San Antonio, Texas, United States

    Contact: Study coordinator (Jordan Georg) · jgeorg@nextoncology.com · 210-580-5921
    Contact: Principal Investigator (Ildefonso Ismael Rodriguez Rivera, MD)

  • NEXT Virginia, Fairfax, Virginia, United States

    Contact: Study coordinator (Maybelle De La Rosa) · mdelarosa@nextoncology.com · 703-783-4518
    Contact: Principal Investigator (Alexander Spira, MD, PhD, FACP)
Study leads

  • Gozde Colak, PhD

    Study Director

    339-707-5855

View source on ClinicalTrials.gov(opens in a new tab)